Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies [Phase 1]
Phase Ib study of YY-20394 in participants with B-cell hematologic malignancies has completed, evaluating safety and preliminary activity ac…
-
CLINICAL_TRIALS trial_result · 2024-06-11Clinical Trial Update: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies [Phase 1]
Phase 1 study of STRO-001, an anti-CD74 antibody-drug conjugate, in advanced B-cell malignancies has been completed.
-
FDA label_change · 2024-06-04FDA Approved: BRUKINSA — Supplemental Application (BeOne Medicines USA, Inc.)
FDA approved a supplemental application for BRUKINSA (zanubrutinib) to update the product labeling.
-
CLINICAL_TRIALS research · 2024-05-29Clinical Trial Update: Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the efficacy of a combination of polatuzumab vedotin, bendamustine, and rituximab in relapsed/refractory m…
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy [NA]
A completed clinical trial evaluating the feasibility of a digital health coaching program for individuals after CAR T-cell therapy.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-05-23Clinical Trial Update: This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma [Phase 2]
This is a Phase II, open-label multicenter study evaluating regimens containing zanubrutinib in newly diagnosed mantle cell lymphoma. The tr…
-
CLINICAL_TRIALS trial_result · 2024-05-21Clinical Trial Update: A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion [Phase 4]
Phase 4 safety study of ibrutinib (Imbruvica) in Indian participants with chronic lymphocytic leukemia or mantle cell lymphoma who have rece…
-
FDA approval · 2024-05-03FDA Approved: BORTEZOMIB — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' generic Bortezomib through an Original Application (ANDA 212204). This approval makes a generic version…
-
CLINICAL_TRIALS withdrawal · 2024-04-25Clinical Trial Update: CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL [Phase 1]
A Phase 1 trial investigating CpG-STAT3 siRNA CAS3/SS3 with localized radiation for relapsed/refractory B-cell non-Hodgkin lymphomas has bee…
-
CLINICAL_TRIALS trial_result · 2024-03-22Clinical Trial Update: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma [Phase 1]
Phase 1 trial evaluating AMG 562 in relapsed/refractory DLBCL, MCL, or follicular lymphoma was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating ibrutinib after intensive induction in previously untreated mantle cell lymphoma patients; status unavailable with …
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies [Phase 1]
Phase 1 clinical trial update examining idelalisib after allogeneic HSCT in B-cell malignancies; the study is terminated with results posted…
-
FDA approval · 2024-02-26FDA Approved: BENDAMUSTINE HYDROCHLORIDE — Supplemental Application (Baxter Healthcare Corporation)
FDA approved a supplemental application for bendamustine hydrochloride (Baxter Healthcare Corporation) under NDA 216078.
-
FDA approval · 2024-02-22FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
The FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
CLINICAL_TRIALS trial_result · 2024-02-12Clinical Trial Update: Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating acalabrutinib in combination with rituximab for elderly patients with untreated mantle cell lymphoma is ongoing (…
-
FDA approval · 2024-02-08FDA Approved: VIVIMUSTA — Supplemental Application (Azurity Pharmaceuticals, Inc.)
The FDA approved a supplemental application for VIVIMUSTA (bendamustine hydrochloride) filed by Azurity Pharmaceuticals, Inc., to update/exp…
-
CLINICAL_TRIALS trial_result · 2024-02-06Clinical Trial Update: Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating loncastuximab tesirine in combination with ibrutinib for diffuse large B-cell lymphoma and mantle cell lymphoma w…
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy [Phase 2]
Phase 2 clinical trial update for MGTA-456 in high-risk hematologic malignancies; results were posted in 2024 and the study is currently act…
-
CLINICAL_TRIALS trial_result · 2024-01-26Clinical Trial Update: Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma [Phase 1]
Phase 1 dose-finding study evaluating the combination of ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lympho…
-
CLINICAL_TRIALS trial_result · 2024-01-23Clinical Trial Update: Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age [Phase 2]
This clinical trial update presents results from a Phase II study evaluating a triplet regimen of bendamustine, rituximab, and venetoclax in…
-
FDA approval · 2024-01-11FDA Approved: BELRAPZO — Supplemental Application (Eagle Pharmaceuticals, Inc)
The FDA approved a supplemental application for Belrapzo (bendamustine hydrochloride) submitted by Eagle Pharmaceuticals, Inc. The action up…
-
CLINICAL_TRIALS trial_result · 2024-01-08Clinical Trial Update: A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma [Phase 1, Phase 2]
A clinical trial evaluating ixazomib in combination with ibrutinib in relapsed/refractory mantle cell lymphoma has completed (Phase 1/Phase …
-
CLINICAL_TRIALS trial_result · 2023-11-24Clinical Trial Update: CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial investigating CD19-targeted CAR T cells for relapsed/refractory mantle cell lymphoma is active not recruiting.
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 trial update of a three-drug combination (acalabrutinib, umbralisib, and ublituximab) for previously untreated mantle cell lymphoma;…
-
CLINICAL_TRIALS trial_result · 2023-10-25Clinical Trial Update: Evaluating Different Doses of Orelabrutinib in MCL [Phase 2]
A Phase 2 trial update evaluating different doses of orelabrutinib in Mantle Cell Lymphoma.